🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Premedication for Less Invasive Surfactant Administration

RecruitingPhase 4Ages any - anyAllUniversity of Oulu
NCT03735563 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Early respiratory management of preterm infants immediately after birth should be as gentle as possible. With this so-called developmental approach, unnecessary invasive methods can be avoided or at least postponed. This kind of "soft landing" allows cardiorespiratory transition with fewer adverse outcomes. Less invasive surfactant administration (LISA) is a technique that involves delivery of surfactant to a spontaneously breathing infant through a thin catheter. This technique minimizes the risk for neonatal lung injury caused by positive pressure ventilation. LISA is nowadays widely used in neonatal intensive care units (NICU). Although less invasive, newborns exposed to this procedure need premedication prior the procedure. There is no consensus, which drug would be the optimal premedication for LISA and the research on this topic is lacking. An ideal premedication would treat the pr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Gestational age at birth ≥26 weeks * Respiratory insufficiency managed with non-invasive respiratory support (nasal continuous positive airway pressure or high-flow) * Requirement for oxygen to maintain oxygen saturation in the target range and need for surfactant treatment (according to clinician's assessment) * If further doses of surfactant are needed, patient can be re-randomized Exclusion Criteria: * Severe RDS with high oxygen requirements, severe respiratory acidosis and/or widespread atelectasis radiologically, such that ongoing ventilator support will be necessary after surfactant therapy (intubation in preferable to LISA if FiO2 \>40% at GA \<28 weeks and \>60% at GA ≥28 weeks) * Maxillo-facial, tracheal or known pulmonary malformations * Any known chromosomal abnormality or severe malformation * An alternative cause for respiratory distress (e.g. congenital pneumonia or pulmonary hypoplasia)
💊

What it tests

  • Ketamine
  • Fentanyl
📍

Where

1 site
Oulu University Hospital
Oulu, Finland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy